Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

@article{Vellenga2011AutologousPB,
  title={Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.},
  author={Edo Vellenga and Wim L J van Putten and Gert Jan Ossenkoppele and Leo F. Verdonck and Matthias Theobald and Jan B. W. J. Cornelissen and Peter C. Huijgens and Johan Maertens and Alois A Gratwohl and Ron Schaafsma and Urs Schanz and Carlos Graux and Harry C. Schouten and Augustin Ferrant and Mario Bargetzi and Martin F. Fey and Bob L{\"o}wenberg},
  journal={Blood},
  year={2011},
  volume={118 23},
  pages={6037-42}
}
We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high-dose cyclophosphamide and busulfan. Of… CONTINUE READING

6 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
Patients with AML ( 16 - 60 years ) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high - dose cyclophosphamide and busulfan .
All Topics